GRAIL, Inc.

NASDAQ:GRAL

Medical - Diagnostics & Research

Healthcare
$102.10 +3.20%

+$1.90 today

Market cap
$4.59B
Beta
3.16
P/E (TTM)
-6.3
EPS (TTM)
-$9.73
52W Low $29.95High $118.84

Volume 0.62M

Average 0.77M

GRAL Deferred Income Tax

The difference between tax expense recognized and tax actually paid in cash during the period.

GRAIL, Inc.NASDAQ: GRAL

Deferred Income Tax · Q2 FY2026 · quarter ended Jun 2026

Deferred income tax growth accelerates

Q2 FY2026 deferred income tax of $56.67M (cash outflow) rose 45.8% year over year, ahead of the -92.2% change in trailing-twelve-month deferred income tax. Sequentially, it rose 64.0% from the prior quarter. Over 3 fiscal years it compounded at +47.8% a year.

Context

  • Deferred income tax amounted to 85.7% of revenue in FY2025, down 21.2 pp from a year earlier.
  • Deferred income tax grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +45.8% holds above the trailing-twelve-month pace of -92.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$56.67M+64.0% QoQ
Last fiscal yearDec 2025
-$126.15M-6.0% YoY
LTMJun 2026
-$12.15M-92.2% YoY
Deferred Income Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+45.8%——
1 year-6.0%——
3-year CAGR+47.8%——
5-year CAGR——
10-year CAGR——

Deferred Income Tax history

USD · from the cash flow

Latest · FY2025
(126.15M) USD
Year-over-year change
+6.0%

Deferred Income Tax vs competitors

How GRAL compares with its peers on the latest reported figures

  • GRAL's LTM Jun 2026 deferred income tax of $12.15M is the largest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of -92.2% is the 3rd highest of 6, against a peer median of -96.6%.
  • Deferred income tax amounts to 7.4% of revenue for GRAL, versus a peer median of 0.0%.
GRAL Competitors Peer median
Deferred Income Tax for GRAL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GRALGRAIL, Inc.LTM Jun 2026$12.15M -92.2%+47.8%7.4%
CSTLCastle Biosciences, Inc.LTM Mar 2026$5.47M -966.6%+49.2%1.6%
FLGTFulgent Genetics, Inc.LTM Mar 2026$2.34M -49.1%—0.7%
MYGNMyriad Genetics, Inc.LTM Mar 2026$1.1M -96.6%+0.5%0.1%
NEONeoGenomics, Inc.LTM Jun 2026$626K -178.7%—0.1%
WGSGeneDx Holdings Corp.LTM Jun 2026$177K +35.1%—0.0%
NTRANatera, Inc.LTM Jun 2026$0 ——0.0%
GHGuardant Health, Inc.LTM Sep 2026$0 ——0.0%
BLLNBillionToOne, Inc.LTM Jun 2026$0 ——0.0%
PSNLPersonalis, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding GRAL) $0-96.6%+24.8%0.0%

Competitors are the stored peer set for GRAL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.25B)(5.4B)(1.47B)(2.03B)(408.35M)
Depreciation & Amortization58.45M154.76M158.7M158.06M156.34M
Deferred Income Tax0(39.06M)(38.15M)(134.25M)(126.15M)
Stock-Based Compensation681.91M75.73M97.24M86.08M58.28M
Change in Working Capital21.59M(14.46M)7.72M(24.28M)12.41M
Accounts Receivables(6.88M)(8.68M)(1.38M)(3.37M)1.69M
Inventory(5.67M)(14.08M)(1.94M)3.07M2.62M
Accounts Payables1.3M2.34M2.89M(14.64M)(2.73M)
Other Working Capital32.85M5.95M8.16M(9.35M)10.84M
Other Non-Cash Items(201M)4.66B644.39M1.36B8.46M
Operating Cash Flow(688.13M)(561.31M)(595.8M)(577.16M)(299.01M)
Capital Expenditures(69.93M)(22.86M)(12.89M)(5.21M)(909K)
Acquisitions (Net)00000
Purchases of Investments000(545.8M)(1.31B)
Sales of Investments00001.22B
Other Investing Activities414.74M0000
Investing Cash Flow344.81M(22.86M)(12.89M)(551.01M)(85.05M)
Debt Repayment00000
Common Stock Issued5.98M000423.32M
Common Stock Repurchased(170K)0000
Dividends Paid00000
Other Financing Activities388.93M604.82M463.77M1.24B0
Financing Cash Flow394.74M604.82M463.77M1.24B423.32M
Effect of Forex Changes(194.61M)(511K)305K(62K)(147K)
Net Change in Cash(143.19M)20.13M(144.62M)116.07M39.12M
Free Cash Flow(758.06M)(584.17M)(608.69M)(582.36M)(299.01M)

GRAIL, Inc.

NASDAQ:GRAL

Intrinsic Alpha fair value

Locked

Current Price

$102.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.